Prognostic Value of Pro-Inflammatory Neutrophils and C-Reactive Protein in Cancer Patient With Coronavirus Disease 2019: A Multi-Center, Retrospective Study
暂无分享,去创建一个
Jianying Chen | Yue Zhang | W. Deng | Yunqiao Li | X. Lei | Yuanhang Yu | S. Hubert | F. Xie | Liang Zhao | Jian-hua Lu | Bo Zhang | Shihua Liu | Yunqiao Li
[1] B. Sahu,et al. C-reactive protein: A promising biomarker for poor prognosis in COVID-19 infection , 2020, Clinica Chimica Acta.
[2] Michael R Hamblin,et al. COVID-19: Transmission, prevention, and potential therapeutic opportunities , 2020, Clinica Chimica Acta.
[3] Zhenyu Li,et al. The role of interleukin‐6 in monitoring severe case of coronavirus disease 2019 , 2020, EMBO molecular medicine.
[4] Shao-bo Shi,et al. Clinical characteristics and outcomes of cancer patients with COVID‐19 , 2020, Journal of medical virology.
[5] S. Kalnicki,et al. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System , 2020, Cancer discovery.
[6] M. Santillana,et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak , 2020, Cancer discovery.
[7] Carl H. June,et al. Cytokine release syndrome in severe COVID-19 , 2020, Science.
[8] Ying Guo,et al. Association of inflammatory markers with the severity of COVID-19 , 2020, medRxiv.
[9] J. M. Crawford,et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps , 2020, The Journal of experimental medicine.
[10] Fang Liu,et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19 , 2020, Journal of Clinical Virology.
[11] L. Cavanna,et al. Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy) , 2020, Future oncology.
[12] C. Wang,et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China , 2020, Annals of Oncology.
[13] T. Guo,et al. Prognostic value of C-reactive protein in patients with COVID-19 , 2020, medRxiv.
[14] Li Zhang,et al. Risk of COVID-19 for patients with cancer , 2020, The Lancet Oncology.
[15] Huahao Shen,et al. Risk of COVID-19 for patients with cancer , 2020, The Lancet Oncology.
[16] Zunyou Wu,et al. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.
[17] Chuan Qin,et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] Ruchong Chen,et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China , 2020, The Lancet Oncology.
[19] Yan Zhao,et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.
[20] Ting Yu,et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.
[21] Jing Zhao,et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.
[22] G. Gao,et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.
[23] F. Greten,et al. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. , 2019, Immunity.
[24] A. Jemal,et al. Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.
[25] Michael S. Goldberg,et al. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice , 2018, Science.
[26] V. Papayannopoulos. Neutrophil extracellular traps in immunity and disease , 2017, Nature Reviews Immunology.
[27] P. Kubes,et al. An emerging role for neutrophil extracellular traps in noninfectious disease , 2017, Nature Medicine.
[28] A. Jemal,et al. Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.
[29] S. Kakkos,et al. Patients With Cancer , 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[30] B. Nordestgaard,et al. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer , 2011, Critical reviews in clinical laboratory sciences.
[31] P. Eckersall,et al. Evaluation of a rapid assay for canine C-reactive protein , 2004, Veterinary Record.
[32] B. Hagberg,et al. CLINICAL CHARACTERISTICS , 1972 .